Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naltrexone
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Naltrexone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 24, 2023
Lead Product(s) : Naltrexone
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naltrexone Hydrochloride,Bupropion Hydrochloride
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Contrave, also marketed as Mysimba is an extended release fixed dose combination of naltrexone HCL/bupropion HCL indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.
Product Name : Contrave
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 18, 2023
Lead Product(s) : Naltrexone Hydrochloride,Bupropion Hydrochloride
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naltrexone Hydrochloride,Bupropion Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CX-101 is an investigational drug that is being studied for smoking cessation.The Phase 3 program builds on the successful Phase 2b findings and evaluates a mixed-weight population at a fixed-dose combination of CX-101 (naltrexone/bupropion 32 mg/360 mg ...
Product Name : Contrave
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2021
Lead Product(s) : Naltrexone Hydrochloride,Bupropion Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sumatriptan
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sumatriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 09, 2017
Lead Product(s) : Sumatriptan
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxepin Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Henry Ford Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Silenor is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 02, 2015
Lead Product(s) : Doxepin Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Henry Ford Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phenazon
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Antipyrine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Otitis Media.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2014
Lead Product(s) : Phenazon
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable